A study to know the efficacy of granisetron in the prevention of post-spinal shivering in caesarean section.
Not Applicable
- Conditions
- Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium
- Registration Number
- CTRI/2021/07/034744
- Lead Sponsor
- Anita Gurung
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Pregnant women of age group 18-45years
2. ASA I and II
Exclusion Criteria
1. Patients with h/o allergy to study drug
2. Cardiac, respiratory disease, renal and neurological disease.
3. Local site infection
4. Spinal deformity
5. Bleeding disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does granisetron utilize to prevent post-spinal shivering in caesarean section patients?
How does granisetron compare to standard-of-care antiemetics in preventing post-spinal shivering during cesarean procedures?
Are there specific biomarkers that can predict granisetron efficacy in preventing post-spinal shivering in obstetric populations?
What are the known adverse events associated with granisetron use in pregnant patients and how are they managed?
What other 5-HT3 receptor antagonists or combination therapies have shown efficacy in preventing post-spinal shivering during cesarean sections?